ImmunityBio (IBRX) Capital Leases (2016 - 2018)

ImmunityBio (IBRX) has 3 years of Capital Leases data on file, last reported at $5.9 million in Q4 2018.

• Capital Leases for Q4 2018 came in at $5.9 million, up 241.47% year-over-year; the trailing twelve-month figure through Dec 2018 was $5.9 million (up 241.47% YoY), and the FY2018 annual result was $5.9 million, up 241.47% from the prior year.
• Capital Leases declined to $5.9 million in Q4 2018 per IBRX's latest filing, from $6.1 million in the prior quarter.
• Over five years, Capital Leases peaked at $6.3 million in Q2 2018 and troughed at $1.7 million in Q1 2018.
• A 3-year average of $3.2 million and a median of $2.0 million in 2016 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2017 and 2018: Capital Leases fell 24.1% in 2017, then surged 241.47% in 2018.
• A 3-year view of Capital Leases shows it stood at $2.0 million in 2016, then fell by 14.02% to $1.7 million in 2017, then surged by 241.47% to $5.9 million in 2018.
• Business Quant data shows IBRX's Capital Leases at $5.9 million in Q4 2018, $6.1 million in Q3 2018, and $6.3 million in Q2 2018.